Development and Characterization of Transdermal Patches Using Novel Thymoquinone-L-Arginine-Based Polyamide Nanocapsules for Potential Use in the Management of Psoriasis
Thymoquinone (TQ) is a phytochemical compound present in Nigella sativa and has potential benefits for treating dermatological conditions such as psoriasis. However, its clinical use is limited due to its restricted bioavailability, caused mainly by its low solubility and permeability. To overcome this, a new transdermal drug delivery system is required. Nanoparticles are known to enhance material solubility and permeability, and hence, this study aimed to synthesize TQ-loaded L-arginine-based polyamide (TQ/Arg PA) nanocapsules incorporated into transdermal patches for prolonged delivery of TQ. To achieve this, Eudragit E polymer, plasticizers, and aloe vera as penetration enhancer were used to develop the transdermal patch. Furthermore, novel TQ/Arg-PA was synthesized via interfacial polymerization, and the resultant nanocapsules (NCs) were incorporated into the matrix transdermal patch. The Arg-PA NCs’ structure was confirmed via NMR and FTIR, and optimal TQ/Arg-PA NCs containing formulation showed high entrapment efficiency of TQ (99.60%). Molecular and thermal profiling of TQ/Arg-PA and the transdermal patch revealed the effective development of spherical NCs with an average particle size of 129.23 ± 18.22 nm. Using Franz diffusion cells and synthetic membrane (STRAT M®), the in vitro permeation profile of the prepared patches demonstrated an extended release of TQ over 24 h, with enhanced permeation by 42.64% when aloe vera was employed. In conclusion, the produced formulation has a potential substitute for corticosteroids and other drugs commonly used to treat psoriasis due to its effectiveness, safety, and lack of the side effects typically associated with other drugs. Graphical Abstract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
AAPS PharmSciTech - 25(2024), 4 vom: 27. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dahmash, Eman Zmaily [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
-arginine |
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1208/s12249-024-02781-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055325327 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055325327 | ||
| 003 | DE-627 | ||
| 005 | 20240424064716.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240328s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1208/s12249-024-02781-2 |2 doi | |
| 035 | |a (DE-627)SPR055325327 | ||
| 035 | |a (SPR)s12249-024-02781-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Dahmash, Eman Zmaily |e verfasserin |0 (orcid)0000-0002-9815-3720 |4 aut | |
| 245 | 1 | 0 | |a Development and Characterization of Transdermal Patches Using Novel Thymoquinone-L-Arginine-Based Polyamide Nanocapsules for Potential Use in the Management of Psoriasis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Thymoquinone (TQ) is a phytochemical compound present in Nigella sativa and has potential benefits for treating dermatological conditions such as psoriasis. However, its clinical use is limited due to its restricted bioavailability, caused mainly by its low solubility and permeability. To overcome this, a new transdermal drug delivery system is required. Nanoparticles are known to enhance material solubility and permeability, and hence, this study aimed to synthesize TQ-loaded L-arginine-based polyamide (TQ/Arg PA) nanocapsules incorporated into transdermal patches for prolonged delivery of TQ. To achieve this, Eudragit E polymer, plasticizers, and aloe vera as penetration enhancer were used to develop the transdermal patch. Furthermore, novel TQ/Arg-PA was synthesized via interfacial polymerization, and the resultant nanocapsules (NCs) were incorporated into the matrix transdermal patch. The Arg-PA NCs’ structure was confirmed via NMR and FTIR, and optimal TQ/Arg-PA NCs containing formulation showed high entrapment efficiency of TQ (99.60%). Molecular and thermal profiling of TQ/Arg-PA and the transdermal patch revealed the effective development of spherical NCs with an average particle size of 129.23 ± 18.22 nm. Using Franz diffusion cells and synthetic membrane (STRAT M®), the in vitro permeation profile of the prepared patches demonstrated an extended release of TQ over 24 h, with enhanced permeation by 42.64% when aloe vera was employed. In conclusion, the produced formulation has a potential substitute for corticosteroids and other drugs commonly used to treat psoriasis due to its effectiveness, safety, and lack of the side effects typically associated with other drugs. Graphical Abstract | ||
| 650 | 4 | |a -arginine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a nanocapsules |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a polyamide |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a psoriasis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a thymoquinone |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a transdermal patch |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Attiany, Lama Murad |e verfasserin |0 (orcid)0000-0003-1005-7943 |4 aut | |
| 700 | 1 | |a Ali, Dalia |e verfasserin |0 (orcid)0000-0001-9680-0026 |4 aut | |
| 700 | 1 | |a Assaf, Shereen M. |e verfasserin |0 (orcid)0000-0002-3888-9330 |4 aut | |
| 700 | 1 | |a Alkrad, Jamal |e verfasserin |4 aut | |
| 700 | 1 | |a Alyami, Hamad |e verfasserin |0 (orcid)0000-0003-3513-4976 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t AAPS PharmSciTech |d Springer International Publishing, 2000 |g 25(2024), 4 vom: 27. März |w (DE-627)SPR02478785X |w (DE-600)2052070-0 |x 1530-9932 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:4 |g day:27 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1208/s12249-024-02781-2 |m X:SPRINGER |x Resolving-System |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |q VZ |
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 4 |b 27 |c 03 | ||